Cardiff Oncology reported positive Phase II data for onvansertib in RAS-mutated metastatic colorectal cancer while simultaneously announcing the departures of its CEO and CFO. The twin disclosures prompted a steep investor reaction: shares plunged roughly 46% in market capitalization over two days, per reporting in StockWatch. The board said the leadership transition aims to position the company for late-stage development and cited the need for executives with relevant late‑stage experience; an interim CEO was named and internal finance continuity measures were announced. Analysts and investors signaled concern about simultaneous management turnover during a critical clinical inflection point, pressuring the stock despite the clinical readout.